Literature DB >> 11448511

Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals.

T Maejima1, T Ohno-Shosaku, M Kano.   

Abstract

Cannabinoid receptors are the molecular targets for the active component Delta(9)-tetrahydrocannabinol of marijuana and hashish, and constitute a major family of G protein-coupled seven-transmembrane-domain receptors. They consist of type 1 (CB1) and type 2 (CB2) receptors of which the CB1 is rich in various regions of the CNS. Accumulated evidence suggests that endogenous cannabinoids function as diffusible and short-lived intercellular messengers that modulate synaptic transmission. Recent studies have provided strong experimental evidence that endogenous cannabinoids mediate signals retrogradely from depolarized postsynaptic neurons to presynaptic terminals to suppress subsequent neurotransmitter release, driving the synapse into an altered state. In hippocampal neurons, depolarization of postsynaptic neurons and resultant elevation of [Ca(2+)](i) lead to transient suppression of inhibitory transmitter release (depolarization-induced suppression of inhibition, DSI). In cerebellar Purkinje cells, on the other hand, depolarization-induced elevation of [Ca(2+)](i) causes transient suppression of excitatory transmitter release (depolarization-induced suppression of excitation, DSE). DSI and DSE appear to share the same properties and may be a general and important mechanism by which the postsynaptic neuronal activity can influence the amount of transmitter release.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448511     DOI: 10.1016/s0168-0102(01)00241-3

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  43 in total

1.  Developmental switch in synaptic mechanisms of hippocampal metabotropic glutamate receptor-dependent long-term depression.

Authors:  Elena D Nosyreva; Kimberly M Huber
Journal:  J Neurosci       Date:  2005-03-16       Impact factor: 6.167

2.  Immunohistochemical localization of cannabinoid CB1 receptor in inhibitory interneurons in the cerebellum.

Authors:  John C Ashton; Ian Appleton; Cynthia L Darlington; Paul F Smith
Journal:  Cerebellum       Date:  2004       Impact factor: 3.847

3.  Miniature synaptic events elicited by presynaptic Ca2+ rise are selectively suppressed by cannabinoid receptor activation in cerebellar Purkinje cells.

Authors:  Miwako Yamasaki; Kouichi Hashimoto; Masanobu Kano
Journal:  J Neurosci       Date:  2006-01-04       Impact factor: 6.167

4.  [Cannabinoids in pain medicine].

Authors:  M Karst
Journal:  Schmerz       Date:  2018-10       Impact factor: 1.107

Review 5.  Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases.

Authors:  Mario van der Stelt; Henrik H Hansen; Wouter B Veldhuis; Peter R Bär; Klaas Nicolay; Gerrit A Veldink; Johannes F G Vliegenthart; Harald S Hansen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

6.  Neuromodulation at single presynaptic boutons of cerebellar parallel fibers is determined by bouton size and basal action potential-evoked Ca transient amplitude.

Authors:  Wei Zhang; David J Linden
Journal:  J Neurosci       Date:  2009-12-09       Impact factor: 6.167

7.  Endocannabinoid signaling in neurotoxicity and neuroprotection.

Authors:  C Pope; R Mechoulam; L Parsons
Journal:  Neurotoxicology       Date:  2009-12-05       Impact factor: 4.294

Review 8.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 9.  Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic anti-inflammatory switch.

Authors:  Renato Malcher-Lopes; Alier Franco; Jeffrey G Tasker
Journal:  Eur J Pharmacol       Date:  2008-01-31       Impact factor: 4.432

10.  Presynaptic cell dependent modulation of inhibition in cortical regions.

Authors:  Afia B Ali
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.